Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer
1996

Evaluation of New Cancer Drugs for Colorectal Cancer

Sample size: 10 publication Evidence: moderate

Author Information

Author(s): AM Burger, JA Double, J Konopa, MC Bibby

Primary Institution: University of Bradford

Hypothesis

Can novel imidazoacridinone derivatives effectively inhibit tumor cell growth in colorectal cancer models?

Conclusion

The study found that C1311 significantly inhibits tumor growth in colorectal cancer models and shows potential for clinical development.

Supporting Evidence

  • C1311 showed significant tumor growth delay in multiple colorectal cancer models.
  • IC50 values for C1311 ranged from 10 nM to 2 µM in human colon cancer cell lines.
  • C1311 was found to bind to calf thymus DNA and inhibit thymidine incorporation in cancer cells.

Takeaway

Scientists tested new drugs to see if they could stop cancer cells from growing, and one of the drugs worked really well.

Methodology

The study involved in vitro and in vivo testing of two imidazoacridinone derivatives, C1310 and C1311, on various human and murine colon carcinoma cell lines.

Limitations

C1310 was less effective in vivo compared to C1311, and the study did not explore all potential mechanisms of action.

Participant Demographics

The study used human and murine colon carcinoma cell lines.

Statistical Information

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication